Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic d...
Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis
About this item
Full title
Author / Creator
Liu, Jianyang , Idborg, Helena , Korotkova, Marina , Lend, Kristina , van Vollenhoven, Ronald , Lampa, Jon , Rudin, Anna , Nordström, Dan , Gudbjornsson, Bjorn , Gröndal, Gerdur , Uhlig, Till , Hørslev-Petersen, Kim , Lund Hetland, Merete , Østergaard, Mikkel , Nurmohamed, Michael and Jakobsson, Per-Johan
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Disease-modifying antirheumatic drugs (DMARDs) are widely used for treating rheumatoid arthritis (RA). However, there are no established biomarkers to predict a patient's response to these therapies. Prostanoids, encompassing prostaglandins, prostacyclins, and thromboxanes, are potent lipid mediators implicated in RA progression. Nevertheless, the...
Alternative Titles
Full title
Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_2260d524aa2942c78c1315d2c24d7266
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2260d524aa2942c78c1315d2c24d7266
Other Identifiers
ISSN
1478-6362,1478-6354
E-ISSN
1478-6362
DOI
10.1186/s13075-024-03295-9
